Abstract
and five negatives when the bridge ELISA assay was used. The three patients who were positive for HACA in the homogenous assay also had low levels of IFX in their serum. Conclusions: A novel non-radiolabeled liquid-phase homogeneous assay with high sensitivity, accuracy and reproducibility has been developed to measure the IFX and HACA levels in serum from patients treated with IFX. This automated assay provides an important tool for clinicians to monitor and relate the clinical status of patients with their HACA and drug levels at any time during the course of treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
